Mereo BioPharma Group plc
NASDAQ Global MarketTotal Valuation
Mereo BioPharma Group plc carries a market capitalization of 48.81M, placing it among publicly traded companies globally. Its enterprise value stands at 3.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 48.81M |
| Enterprise Value | 3.74M |
Share Statistics
Mereo BioPharma Group plc currently has 798.08M shares outstanding.
| Shares Outstanding | 798.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 79.93, and the price-to-book ratio stands at -0.08.
| PE Ratio | N/A |
| PS Ratio | 79.93 |
| PB Ratio | -0.08 |
| P/TBV Ratio | 1.19 |
| P/FCF Ratio | -1.50 |
| P/OCF Ratio | -1.48 |
Enterprise Valuation
| EV / Sales | 7.49 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Mereo BioPharma Group plc maintains a current ratio of 6.48, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.48 |
| Quick Ratio | 6.17 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -365.55 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -65.56 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Mereo BioPharma Group plc's stock has declined approximately -82.625% over the past 52 weeks. The 50-day moving average sits at 0.30, while the 200-day moving average is 0.85.
| Beta (5Y) | N/A |
| 52-Week Price Change | -82.625% |
| 50-Day Moving Average | 0.30 |
| 200-Day Moving Average | 0.85 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Mereo BioPharma Group plc generated 500,000.00 in revenue and converted that into -35.71M in net income, yielding earnings per share of -0.22. EBITDA reached -34.73M, while operating income came in at -35.91M.
| Revenue | 500,000.00 |
| Gross Profit | 368,000.00 |
| Operating Income | -35.91M |
| Pretax Income | -35.71M |
| Net Income | -35.71M |
| EBITDA | -34.73M |
| EBIT | -35.91M |
| Earnings Per Share (EPS) | -0.22 |
Balance Sheet
Total book value stands at -504.39M, with working capital of 33.86M providing operational flexibility.
| Cash & Cash Equivalents | 36.22M |
| Total Debt | N/A |
| Net Debt | -36.22M |
| Equity (Book Value) | -504.39M |
| Book Value Per Share | -3.15 |
| Working Capital | 33.86M |
Cash Flow
Mereo BioPharma Group plc produced -26.95M in operating cash flow over the past twelve months. After subtracting -300,000.00 in capital expenditures, free cash flow totaled -27.25M - equivalent to -0.17 per share.
| Operating Cash Flow | -26.95M |
| Capital Expenditures | -300,000.00 |
| Free Cash Flow | -27.25M |
| FCF Per Share | -0.17 |
Margins
Mereo BioPharma Group plc operates with a gross margin of 73.60, reflecting its pricing power and cost economics. The operating margin of -7,182.20 and net profit margin of -7,142.00 provide insight into operational efficiency.
| Gross Margin | 73.60 |
| Operating Margin | -7,182.20 |
| Pretax Margin | -7,142.00 |
| Profit Margin | -7,142.00 |
| EBITDA Margin | -6,945.40 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.24 |
| FCF Yield | -66.69 |
Scores
Mereo BioPharma Group plc posts an Altman Z-Score of -15.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -15.93 |